CDLX Earnings Prediction
The chart below shows how CDLX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CDLX sees a +7.04% change in stock price 10 days leading up to the earnings, and a -11.79% change 10 days following the report. On the earnings day itself, the stock moves by -2.15%. This data can give you a slight idea of what to expect for the next quarter's release.
CDLX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
CDLX Earnings Analysis
Cardlytics Inc Corporation (CDLX.O) Earnings Conference Call
Positive
Strong Q4 Performance: We exceeded the high end of our guidance across all metrics in Q4, driven by higher-than-expected pipeline wins and improved delivery of our platform.
UK Business Growth Highlights: The UK business showed strong double-digit growth, particularly in the everyday spend category, which is a strength of our business.
New Neobank Partnership: We signed a new Neobank partner in Q4, one of the fastest growing fintechs in the U.S., and expect to scale quickly with them by the end of Q1.
Brand Engagement Surge: We saw a 50% increase in brands using our insights portal, indicating strong interest and engagement from advertisers.
Advertiser Growth Success: In Q4, we achieved the highest number of total advertisers since 2022, indicating successful diversification of our content.
Revenue-to-Billings Margin Improvement: We improved our revenue-to-billings margins by 3.7 points from the previous quarter, reflecting better rewards management.
Improved Contribution Margin: Our adjusted contribution margin was 55%, up 2.5 points due to a more favorable partner mix, showcasing improved profitability.
Positive Operating Cash Flow: Operating cash flow was positive at $3 million, indicating better cash management and operational efficiency.
Strong Liquidity Position: We ended Q4 with over $100 million of liquidity, providing a strong financial position to support operations and growth initiatives.
Negative
Earnings Miss Report: Cardlytics, Inc. misses on earnings expectations with reported EPS of $-0.30566, falling short of the expected $-0.24.
Decline in Total Billings: In Q4, total billings decreased by 11.2% year-over-year, indicating a decline in overall business performance.
U.S. Revenue Decline: U.S. revenue decreased by 19.9% due to lower billings and higher redemptions, reflecting challenges in the U.S. market.
Revenue Decline Analysis: Bridg revenue declined by 12.7% compared to the prior year, attributed to the loss of key accounts in early 2024.
EBITDA Decline in Profitability: Adjusted EBITDA declined from $10.3 million to $6.4 million, showing a decrease in profitability.
Decline in Consumer Incentives: Consumer incentives decreased by 1.2% to $42.3 million, which may indicate challenges in maintaining consumer engagement.
Decline in ARPU: ARPU (Average Revenue Per User) was down 16.7% to $0.44, reflecting increased consumer incentives and potentially lower monetization.
Negative Billings Growth Outlook: For Q1, billings guidance indicates a negative growth rate of 10% to 13%, suggesting continued struggles in the upcoming quarter.
Challenging Q1 Performance: The company expects Q1 to represent the trough of their performance, indicating a challenging start to 2025.
CDLX FAQs
How does CDLX typically perform around its earnings report dates?
Is Cardlytics Inc (CDLX) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CDLX Earning Call Sentiment
Cardlytics, Inc. (NASDAQ:CDLX) Q4 2024 Earnings Call Transcript
CDLX.O
-4.45%Positive
The earnings call reveals several concerning factors: a missed EPS expectation, declining revenue, and a negative growth outlook for Q1. Despite some positive developments like new partnerships and improved delivery, the lack of a share buyback or dividend program, coupled with weak guidance and cautious financial health, suggests a negative sentiment. The Q&A section highlighted management's vague responses, particularly regarding Dosh's contributions and micro-targeting opportunities, further dampening confidence.
